Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Martina Bio Genics Pvt Ltd

    Martina Bio Genics Pvt. Ltd., is a WHO GMP Certified company started its journey from the year 2006. Its manufacturing facility is located in a site area of more than 3 acres in

  • No Image
    Maschmeijer Aromatics India Ltd

    Maschmeijer Aromatics India Limited was setup in 1960 in collaboration with the world famous Maschmeijer Aromatics B.V., Amsterdam for the manufacture of musks and fragrances. A

  • No Image
    Maysa Labs Pvt Ltd

    Maysa Labs Private Limited (originally known as Maysa Impex Pvt Ltd) was established in March 2013 at Hyderabad, Telangana. It commenced operations by acquiring Sravani Labs Pvt

  • No Image
    Medicamen Biotech Ltd

    Medicamen Biotech Limited is a widely held, globally recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and dome